AI Article Synopsis
Article Abstract
Introduction: During the Global War on Terrorism, many US Military service members sustained injuries with potentially long-lasting functional limitations and chronic pain. We sought to understand the patterns of prescription opioid use among service members injured in combat.
Methods: We queried the Military Health System Data Repository to identify service members injured in combat between 2007 and 2011. Sociodemographics, injury characteristics, treatment information, and costs of care were abstracted for all eligible patients. We surveyed for prescription opioid utilization subsequent to hospital discharge and through 2018. Negative binomial regression was used to identify factors associated with cumulative prescription opioid use.
Results: We identified 3,981 service members with combat-related injuries presenting during the study period. The median age was 24 years (interquartile range [IQR], 22-29 years), 98.5% were male, and the median follow-up was 3.3 years. During the study period, 98% (n = 3,910) of patients were prescribed opioids at least once and were prescribed opioids for a median of 29 days (IQR, 9-85 days) per patient-year of follow-up. While nearly all patients (96%; n = 3,157) discontinued use within 6 months, 91% (n = 2,882) were prescribed opioids again after initially discontinuing opioids. Following regression analysis, patients with preinjury opioid exposure, more severe injuries, blast injuries, and enlisted rank had higher cumulative opioid use. Patients who discontinued opioids within 6 months had an unadjusted median total health care cost of US $97,800 (IQR, US $42,364-237,135) compared with US $230,524 (IQR, US $134,387-370,102) among those who did not discontinue opioids within 6 months (p < 0.001).
Conclusion: Nearly all service members injured in combat were prescribed opioids during treatment, and the vast majority experienced multiple episodes of prescription opioid use. Only 4% of the population met the criteria for sustained prescription opioid use at 6 months following discharge. Early discontinuation may not translate to long-term opioid cessation in this population.
Level Of Evidence: Epidemiology study, level III.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/TA.0000000000003133 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trends in naloxone co-prescriptions.
Drug Alcohol Depend
December 2024
Stanford University School of Medicine, Office of PA Education, 300 Pasteur Drive, Stanford, CA, United States; Stanford University School of Medicine, Department of Medicine, Division of Primary Care and Population Health, 300 Pasteur Drive, Stanford, CA, United States; Kaiser Permanente Mountain View Medical Offices, Department of Internal Medicine, 555 Castro Street, Mountain View, CA, United States. Electronic address:
Background: The opioid epidemic remains a significant public health crisis in the United States. Naloxone has been identified as a critical component in combating this crisis. However, co-prescription rates among patients receiving opioids remain suboptimal, especially among certain high-risk populations.
View Article and Find Full Text PDFOpioid prescribing prevalence and initiation rates in Victoria, Australia: insights from primary care data during a period of opioid policy changes (2017-2022).
Int J Clin Pharm
December 2024
Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Level 2 Building D, 47-49 Moorooduc Highway, Frankston, Melbourne, VIC, 3199, Australia.
Background: Opioid medications are widely prescribed for acute, chronic and cancer pain. In Australia, opioid prescribing rates remain high.
Aim: This study aimed to document patterns of primary care opioid prescribing from 2017 to 2022 by demographic characteristics in Victoria, Australia.
Evaluating the use of sublingual sufentanil in patients with buprenorphine treatment who are undergoing ambulatory surgery: A Prospective Case Report.
Orthop Rev (Pavia)
December 2024
Anesthesiology Montefiore Medical Center, Albert Einstein College of Medicine.
Introduction: Opioid use disorder is a chronic illness with significant morbidity and mortality. Opioid agonists, like buprenorphine, are commonly used to prevent relapse. Recent changes in buprenorphine legislation are expected to increase prescription and guidelines recommend its continuation during the perioperative period for many patients.
View Article and Find Full Text PDFCatalyzing Pharmacogenomic Analysis for Informing Pain Treatment (C-PAIN): A Randomized Trial of Preemptive Genotyping in Cancer Palliative Care.
J Pain Res
December 2024
Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, IL, USA.
Background: Cancer patients frequently suffer from pain, often managed with opioids. However, undertreated pain remains a significant concern. Opioid effectiveness varies due to genetic differences in how individuals metabolize some of these medications.
View Article and Find Full Text PDFFrailty Status, Not Just Age, is Associated With Postoperative Opioid Consumption: A Retrospective, Population-based Analysis.
Ann Surg Open
December 2024
Department of Surgery, University of Michigan, Ann Arbor, MI.
Objective: To assess the relationship between postoperative opioid consumption and frailty status.
Background: Physiologic reserve can be assessed through both chronologic age as well as measures of frailty. Although prior studies suggest that older individuals may require less opioid following surgery, chronologic age, and frailty do not always align, and little is known regarding postoperative opioid consumption patterns by frailty.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!